# UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH: A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH |
| Location | SALT LAKE CITY, UT |
| Project | A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease |
| Project number | 5U01NS120901-05 |
| Mechanism | U01 |
| Institute | National Institute of Neurological Disorders and Stroke |
| Award | $4,499,712 |
| Awarded | 2026-09-02 |
| Project period | 2021-09-15 to 2027-08-31 |
| UEI | LL8GLEVH6MG3 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11395496). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.